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Mutations or loss of heterozygosity of p53 are detected in approximately 50% of bladder cancers. E1B-55 kD-deleted adenovirus has
been shown to kill tumour cells with defective p53 function while sparing normal cells. Here, we examined the cytolytic effect and
replication of E1B-55 kD-deleted adenovirus, designated Ad5WS1, on human bladder cancer cell lines with various p53 status.
Ad5WS1 caused more severe cytolytic effect and replicated more efficiently in J82 and TCC-SUP bladder cancer cells carrying
mutant p53 compared with TSGH-8301 and BFTC-905 bladder cancer cells retaining wild-type p53. Introduction of dominant
negative p53 into BFTC-905 cells rendered them more susceptible to Ad5WS1-induced cytolysis. Furthermore, cells susceptible to
lysis caused by Ad5WS1 were not attributable to their greater infectability by adenovirus. Finally, Ad5WS1 suppressed the growth of
TCC-SUP bladder tumour xenografts, which could be augmented when combined with replication-defective adenoviral vector
encoding kringles 1–5 of plasminogen (K1–5), an angiogenic inhibitor. Taken together, our results show that E1B-55 kD-deleted
adenovirus replicates and hence lyses bladder cancer cells with mutant p53 much more efficient than those with wild-type p53. Thus,
E1B-deleted adenovirus may have therapeutic potential, especially in combination with adenoviral vector expressing K1–5, for the
treatment of bladder cancer.
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Transitional cell carcinoma (TCC) of the bladder is a common
cause of death of genitourinary tumours. The generally poor
prognosis of advanced bladder cancer indicates the need for new
therapeutic modalities. Mutations in the p53 gene are the most
common genetic defect in human bladder cancer, which occur in
approximately 50% of bladder cancer and are associated with high-
stage, high-grade TCC (Sidransky et al, 1991; Esrig et al, 1994). In
accordance with the important role of p53 in bladder carcinogen-
esis, loss of heterozygosity of 17p, where p53 gene is located, is
detected in more than 60% of patients with poorly differentiated
tumours (Olumi et al, 1990). There is a significant correlation
between the mutations in the p53 gene and increased microvessel
counts in patients with invasive bladder cancer (Bochner et al,
1997). Furthermore, p53 exerts its tumour suppressor effects, in
part, through the control of bladder tumour angiogenesis
(Grossfeld et al, 1997). Therefore, angiogenesis may be one of
the therapeutic targets for treating bladder cancer.
The E1B-55 kD protein of adenovirus is able to bind and
inactivate p53, and thus allows adenovirus to replicate in cells
without the restrain of p53 growth control. Bischoff et al (1996)
first reported that E1B-55 kD-deleted adenovirus selectively
replicated in and lysed cancer cells lacking functional p53 while
sparing normal cells. However, subsequent investigations have
suggested that replication of this mutant adenovirus may not be
entirely dependent upon p53 status (Rothmann et al, 1998; Harada
and Berk, 1999). Despite controversy concerning the mechanisms
underlying the replication of E1B-55 kD-deleted adenovirus in
tumour cells, it is currently employed for cancer therapy, and
clinical trials have been promising, especially combined with
chemotherapy or radiotherapy (Khuri et al, 2000; Habib et al,
2001). Notably, no virus was detected in the normal tissue
examined in clinical trials (Khuri et al, 2000).
Targeting angiogenesis to kill tumour cells is one of the
promising therapeutic approaches for cancer. Angiostatin com-
prising the first four kringles of plasminogen is an endogenous
inhibitor of angiogenesis that inhibits the growth of primary and
metastatic tumours (O’Reilly et al, 1994). A plasminogen fragment
containing kringles 1–5 (K1–5) has been shown to exhibit higher
antiangiogenic activity and hence higher antitumour effect
compared with angiostatin (Cao et al, 1999). Targeting tumour
vasculature with antiangiogenic gene therapy has become a
promising new approach for cancer therapy.
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sBased on the fact that most bladder cancers have mutation in the
p53 gene, in this study we examined the cytolytic effect of E1B-55
kD-deleted adenovirus on bladder cancer cells with various p53
status. We demonstrate that this mutant adenovirus exerted a p53-
dependent cytolytic effect on bladder cancer cells and its
antitumour effect could be augmented when combined with E1-
deleted adenoviral vector encoding K1–5. Therefore, our results
suggest that E1B-55 kD-deleted adenovirus may have therapeutic
potential, especially in combination with replication-defective
adenoviral vector expressing K1–5, for the treatment of patients
with bladder cancer.
MATERIALS AND METHODS
Cell lines and mice
TSGH-8301 (Yeh et al, 1988) and BFTC-905 (Tzeng et al, 1996)
cells carry wild-type p53, while J82 and TCC-SUP cells harbour
mutant p53 (Rieger et al, 1995; Markl and Jones, 1998). BFTC-173-
12 cells were derived from BFTC-905 cells by transfection with
V173L, an expression plasmid of a dominant-negative mutant p53
with a substitution of leucine for valine at codon 173 (Chen et al,
1993), followed by selection of stable transfectants with G418
(Chang and Lai, 2001). All the bladder cancer and 293 cells were
cultured in Dulbecco’s modified Eagle’s medium containing 10%
fetal bovine serum, 2mM glutamine and 50mgml
 1 gentamicin.
Female BALB/cByJ SmnPrkdc SCID mice at the age of 6–10 weeks
used for TCC-SUP tumour cell implantation were obtained from
the Laboratory Animal Center of the National Cheng Kung
University. The animals were maintained in specific pathogen-
free animal care facility under isothermal conditions with regular
photoperiods. The experimental protocol adhered to the rules of
the Animal Protection Act of Taiwan and was approved by the
Laboratory Animal Care and Use Committee of the National Cheng
Kung University, in full accordance with the UK Guidelines for the
Welfare of Animals in Experimental Neoplasia (Workman et al,
1998).
Construction of recombinant adenoviruses
The E1B-55 kD-deleted adenovirus, designated Ad5WS1, was
constructed as described previously (Hsieh et al, 2003). The E1-
deleted adenoviral vector encoding K1–5, designated Ad/K1–5,
was constructed as follows. The coding region of murine K1–5 was
generated from pRR1/plasminogen (ATCC, Manassas, VA, USA)
by PCR with sense primer 50-CCC AAG CTT GGA TCC CAT GAA
GAG AGT GTA TCT GTC AGA, which introduced a HindIII site
and an ATG start codon, and antisense primer 50-GCT CTA GAA
TTC TCA TCT GGG GTT TGT TGT ATA GC, which introduced an
XbaI site and a stop codon. The resulting 1.4-kb DNA fragment
was digested with HindIII and XbaI, and cloned into the
adenovirus shuttle vector pAd5L at the HindIII/XbaI sites,
resulting in pAd5L/K1–5. The pAd5L/K1–5 plasmid was cotrans-
fected with pJM17 into 293 cells to generate Ad/K1–5 (Hitt et al,
1998). The E1-deleted adenoviral vector Ad/LacZ encoding
b-galactosidase (b-gal) was also used. All the recombinant
adenoviruses were propagated and subsequently quantified by
plaque assay in 293 cells as previously described (Hitt et al, 1998).
Assays of cytopathic effect (CPE), cell viability
and viral replication
Cells cultured in six-well plates were infected with Ad5WS1 at
0.001, 0.01, 0.1 and 1 multiplicities of infection (MOIs) for 2h.
Cells were observed daily for CPE. Once the CPE was evident,
which took 5–9 days, cells were stained with 10% formalin/0.05%
crystal violet solution. The viable cell numbers were also
determined in cells seeded in six-well plates after 3 days of
Ad5WS1 infection at an MOI of 2 by trypan blue exclusion. Viral
replication was assayed as previously described (Hsieh et al, 2003).
Briefly, confluent cells in six-well plates were infected with
Ad5WS1 at an MOI of 2. Viruses harvested from both the
supernatant and cell lysate at 26h postinfection were pooled and
titered on 293 cells by 50% tissue culture infective dose (TCID50)
method.
Determination of infectability of human bladder cancer
cell lines by adenovirus
To determine the infectability by adenovirus, bladder cancer cells
cultured in 24-well plates were infected with various doses of
Ad/LacZ in triplicate and incubated for 48h, after which the cells
were stained for b-gal activity (Hashimoto et al, 1997). Infectability
was expressed as a percentage by dividing the number of b-gal-
expressing cells by the total number of cells from three separate
microscopic fields at a magnification of  200.
Chorioallantoic membrane (CAM) assay
The angiogenesis assay was carried out as previously described
(Shing et al, 1985). Ad/K1–5 or Ad/LacZ at a dose of 2 10
7
plaque-forming units (PFU), or PBS was implanted onto the CAMs
of a 6-day-old chick embryo through a window made in the egg
shell. The CAMs were photographed and analysed for angiogenesis
after incubation for 24h at 371C.
Immunohistochemical and vascular staining
At 48h after infection with Ad/K1–5 at an MOI of 2, TCC-SUP
cells were fixed in 3.7% formaldehyde, treated with cold acetone,
and quenched in 3.7% H2O2 for detection of K1–5 expression by
immunohistochemical staining using rabbit antibody against
human plasminogen kringles 1–3 (K1–3). To evaluate K1–5
expression in tumours, TCC-SUP cells (10
7 cells) were inoculated
subcutaneously (s.c.) into the flank of SCID mice at day 0. At day
10, mice were injected intratumorally with Ad/K1–5 at a dose of
10
8 PFU for 5 consecutive days. At day 17, tumours were excised
and snap frozen. Cryostate sections (4mm) were prepared and
incubated with rabbit antibody against K1–3 followed by detection
with the DAKO LSAB 2 System (DAKO, Carpinteria, CA, USA)
according to the manufacturer’s instructions. After sequential
incubation with biotinylated secondary antibody, horseradish
peroxidase-labelled streptavidin, and aminoethyl carbazole (AEC)
as substrate chromogen, the slides were counterstained with
haematoxylin. For vascular staining, the slides were incubated with
polyclonal anti-factor VIII (von Willebrand’s factor, DAKO),
peroxidase-labelled goat anti-rabbit IgG (H & L chain specific,
Calbiochem, Darmstadt, Germany), followed by application of
AEC, and counterstaining with haematoxylin. Stained blood
vessels were counted in three blindly chosen random fields at
 40 magnification, and the mean and s.d. of the counts were
calculated.
Animal studies
TCC-SUP cells (10
7) were inoculated s.c. into the flank of SCID
mice at day 0. At day 8, visible and palpable nodules developed at
all injection sites ranging from 25.08 to 47.71mm
3, with mean
tumour volume of 31.8976.45mm
3. Groups of seven mice were
treated intratumorally with Ad5WS1 (10
8 PFU in 100ml of PBS) or
Ad/K1–5 (2.5 10
8 PFU in 100ml of PBS) alone for 5 consecutive
days, or with Ad5WS1 (10
8 PFU in 100ml of PBS) at days 8, 10 and
12 plus Ad5WS1 (10
8 PFU in 50ml of PBS) admixed with Ad/K1–5
(2.5 10
8 PFU in 50ml of PBS) at days 9 and 11. As the injection
volume of adenovirus correlates with intratumoral virus distribu-
tion, and hence influences therapeutic efficacy (Heise et al, 1999),
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sin this study the volume for each intratumoral injection was fixed
to 100ml. All mice were monitored for tumour growth after tumour
inoculation. Palpable tumours were measured once a week in two
perpendicular axes with a tissue caliper and the tumour volume
was calculated as (length of tumour) (width of tumour)
2 0.45.
The mice were killed by intraperitoneal injection of pentobarbital
at day 58, when tumours reached approximately 1.7cm in mean
diameter in PBS-treated group.
Statistical analysis
Tumour volumes and vessel density were compared using an
unpaired, two-tailed Student’s t-test. Any P-values less than or
equal to 0.05 were regarded as statistically significant.
RESULTS
CPE in bladder cancer cells infected with Ad5WS1
The cytolytic effect of Ad5WS1 on four bladder cancer cell lines
with different p53 status was examined. At an MOI of 2, Ad5WS1
caused CPE in J82 and TCC-SUP cells carrying mutant p53, but not
in TSGH-8301 and BFTC-905 cells retaining wild-type p53 at 5 days
postinfection (Figure 1). At 7 days after infection, Ad5WS1
completely lysed 293 cells at MOIs ranging from 0.01 to 10
(Figure 2A). It lysed TCC-SUP and J82 cells in a dose-dependent
manner, with complete cytolysis at an MOI of 10 at 5–7 days
postinfection (Figure 2B and C). Nevertheless, even when
monitored for 9 days, no significant CPE was observed in TSGH-
8301 and BFTC-905 cells infected with Ad5WS1 at the same MOIs
(Figure 2D and E). However, at an MOI of 10, Ad5WS1 caused
some CPE, albeit only to a very small extent, in TSGH-8301 and
BFTC-905 cells (Figure 2D and E). These results indicate that
bladder cancer cells carrying mutant p53 were more susceptible to
Ad5WS1-induced cytolysis compared with those carrying wild-
type p53.
Replication of Ad5WS1 in bladder cancer cells
The ability of Ad5WS1 to replicate in four bladder cancer cell lines
was assessed at 26h postinfection. As shown in Figure 3, Ad5WS1
replicated and produced high titers on both J82 and TCC-SUP
cells. Viral yield did not differ between TCC-SUP and 293 cells
infected with Ad5WS1. Of note, viral yield produced in J82 cells
was found to be 10.34-fold higher over that in 293 cells. However,
viral replication was only 0.87% and 1.52% in TSGH-8301 and
BFTC-905 cells, respectively, as compared with that in 293 cells.
Collectively, Ad5WS1 replicated more efficiently in bladder cancer
cells with mutant p53 than in those with wild-type p53.
CPE in mutant p53 transfectant infected with Ad5WS1
Further evidence to support the notion that mutation of p53 in
cells renders them more sensitive to Ad5WS1-induced cytolysis is
presented in Figure 4. BFTC-173-12 cells, which harboured
dominant-negative p53, exhibited severe CPE following Ad5WS1
infection (Figure 4A), whereas no significant CPE was noticed in
parental BFTC-905 cells (Figure 1). In BFTC-173-12 cells infected
with Ad5WS1, the number of viable cells decreased to 50% at 3
days postinfection compared with mock-infected cells, whereas the
viability of Ad5WS1-infected BFTC-905 cells was not significantly
different from mock-infected cells (Figure 4B). In terms of
virus replication, viral yields in BFTC-173-12 and BFTC-905
cells were 1.58 10
6 and 1.58 10
3 TCID50ml
 1 at 26h postinfec-
tion, respectively. These results demonstrate that the mutant
p53 transfectant was more permissive for Ad5WS1 replication
than parental cells with wild-type p53, thus resulting in more
cytolysis.
Infectability of bladder cancer cells by adenovirus
The observed differences in the susceptibility of various human
bladder cancer cells to Ad5WS1-induced cytolysis could be
attributable to various levels of cell infectability by adenovirus
among different cell lines. To address this question, we examined
the infectability of the cells by Ad/LacZ, a recombinant adenoviral
vector carrying the b-gal reporter gene. As shown in Figure 5,
b-gal expression was detectable, albeit at different levels, in all of
the cells examined after exposure to Ad/LacZ. Furthermore, the
infectability of the cells increased when higher doses of Ad/LacZ
were applied. The most notable difference was found in TSGH-
8301 cells that exhibited three times more infectable with
adenovirus compared with J82 cells, which were the least infectable
cells. The infectability between BFTC-173-12 and BFTC-905 did not
differ, suggesting that introduction of dominant-negative p53 in
the BFTC-905 cells, to obtain the stable BFTC-173-12 transfectant,
did not change the infectability of the cells compared with the
parental cells.
Functional characterisation of K1–5 expressed
by Ad/K1–5
Expression of K1–5 was detectable in more than 80% of TCC-SUP
cells transduced with Ad/K1–5 (Figure 6A) compared with
untransduced cells (Figure 6B). Expression of K1–5 in tumours
was further examined in TCC-SUP tumour-bearing SCID mice
treated with Ad/K1–5. By immunohistochemical staining, K1–5
J82 TCC-SUP
Mock
Ad5WS1
Mock
Ad5WS1
TSGH-8301 BFTC-905
Figure 1 Cytopathic effect (CPE) in human bladder cancer cell lines after
Ad5WS1 infection. Cells were infected with Ad5WS1 at an MOI of 2 and
monitored for CPE by photomicrographic examination at 5 days
postinfection ( 200 magnification).
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sprotein was detectable in the tumour xenografts from Ad/K1–5-
treated (Figure 6C), but not PBS-treated mice (Figure 6D).
Furthermore, tumour xenografts were analysed for microvessel
morphology and vascularisation by staining for factor VIII.
Tumour sections from Ad/K1–5-treated mice appeared much less
vascularised (Figure 6E and G) than their PBS-treated counterparts
(Figure 6F and H). The vessel density underneath tumour capsules
was markedly reduced in Ad/K1–5-treated (1272.65 vessels per
field) compared with PBS-treated (32.6772.52 vessels per field)
tumours (Po0.001). Furthermore, K1–5 encoded by Ad/K1–5
inhibited angiogenesis in the CAM assay. Ad/K1–5 inhibited the
growth of embryonic new blood vessels (Figure 7A) compared with
Ad/LacZ-treated (Figure 7B) or PBS-treated (Figure 7C) CAMs.
Ad/K1–5 inhibited angiogenesis in four of six CAMs, while only
one of six CAMs in Ad/LacZ-treated group revealed suppression of
neovascularization, and none was found in PBS-treated CAMs.
Taken together, these results indicate that the expressed K1–5
mediated by Ad/K1–5 gene transfer was detectable and displayed
antiangiogenic activity in vitro and in vivo.
MOI 10 1 0.1 10 1 0.1 10 1 0.1
0.01 0.001 Mock 0.01 0.001 Mock 0.01 0.001 Mock
MOI 10 1 0.1
0.01 0.001 Mock 0.01 0.001 Mock
10 1 0.1
A B C
D E
293 TCC-SUP J82
TSGH-8301 BFTC-905
Figure 2 Cytopathic effect (CPE) in human bladder cancer and 293 cell lines after Ad5WS1 infection at different MOIs. Cells were infected with
increasing MOIs and monitored for CPE by crystal violet staining at 5–9 days postinfection.
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Figure 3 Relative titre of Ad5WS1 on various bladder cancer cell lines
compared with 293 cells. Viral replication in bladder cancer and 293 cells
infected with Ad5WS1 at an MOI of 2 was determined 26h later. Viral
titres were determined on 293 cells by TCID50 method. Results are
presented as the titre of the virus determined on 293 cells in each cell line
normalised to that in 293 cells. Each value represents the mean of three
independent experiments7s.d.
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Figure 4 Effects of Ad5WS1 on BFTC-905 cells and BFTC-173-12 cells
carrying dominant-negative p53.( A) CPE in BFTC-173-12 cells infected
with Ad5WS1. BFTC-173-12 cells were infected or mock-infected with
Ad5WS1 at an MOI of 2 and monitored for CPE by photomicrographic
examination at 3 days postinfection ( 200 magnification). (B) Cell viability
in BFTC-905 and BFTC-173-12 cells after Ad5WS1 infection at an MOI of
2. The viable cell numbers were determined after 3 days by trypan blue
exclusion.
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sAntitumour effects of Ad5WS1 and Ad/K1–5
The antitumour effects of Ad5WS1 alone or combined with
Ad/K1–5 were examined in pre-established human TCC-SUP
bladder tumour xenografts. As shown in Figure 8, TCC-SUP
tumours from either Ad5WS1-treated (P¼0.00027) or Ad/K1–5-
treated (P¼0.00024) mice were significantly smaller than those
from PBS-treated mice. Furthermore, at day 58 combination
treatment of Ad5WS1 and Ad/K1–5 inhibited tumour growth
compared with Ad5WS1-treated (P¼0.05) or Ad/K1–5-treated
(P¼0.0018) mice. Of note, complete tumour regression was
observed in one of seven established tumours in the combined
treatment group, but not in the remaining three treatment groups
(data not shown).
DISCUSSION
In the work described here, Ad5WS1 caused more severe CPE and
produced higher viral yield in cells carrying mutant p53 compared
with those carrying wild-type p53. At an MOI equal to or less than
2, the CPE caused by Ad5WS1 in human bladder cancer cell lines
appeared to be p53-dependent. However, at very high viral doses
and an extended period of infection, Ad5WS1 also caused some
CPE, albeit only to a very small extent, in BFTC-905 and TSGH-
8301 cells with wild-type p53. Studies along this line demonstrated
that E1B-deleted adenovirus can infect tumour cells with
functional p53 at higher viral doses, while kill those carrying
nonfunctional p53 at much lower doses in hepatocellular
carcinoma and lung cancer cell lines (Vollmer et al, 1999; You
et al, 2000). It has been demonstrated that when sufficient E1B-55
kD-deleted viral particles are delivered and sufficient target cells
are in the S phase of the cell cycle, the virus may replicate
regardless of the p53 status of target cells (Goodrum and Ornelles,
1997). In the viral replication assay shown here, compared with
cancer cells harbouring wild-type p53, the observed CPE caused by
Ad5WS1 in bladder cancer cells carrying mutant p53 corresponded
to as much as 1000-fold difference in virus yield. Our results also
indicate that infectious E1B-deleted adenoviruses may still be
produced to a small extent in cells harbouring wild-type p53,
despite the absence of an obvious CPE, which were in accordance
with previous findings (Bischoff et al, 1996; Ganly et al, 2001).
Since most related reports do not include quantitative evidence of
viral replication and the production of new virus in the cancer cell
lines studied, the relation between p53 status and viral replication
or CPE still awaits clarification.
The infectability of cell lines by adenovirus has been reported to
be dependent on the presence of coxsackie and adenovirus
receptor (CAR) and avb integrins, which are two cell membrane
components involved in viral attachment and internalisation
(Wickham et al, 1993; Bergelson et al, 1997). It has been shown
that a wide spectrum of CAR levels exists among human bladder
cancer cells, which may correlate with their sensitivity to
adenovirus infection (Li et al, 1999). Our results argue against
the possibility that the infectability levels of the human bladder
cancer cell lines by adenovirus contribute to their susceptibility to
cytolysis induced by Ad5WS1. In this study, Ad5WS1 replicated
efficiently and caused cytolysis in TCC-SUP but not in BFTC-905
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Figure 5 Infectability of human bladder cancer cell lines by Ad/LacZ
adenoviral vector. Cells were infected with AdLacZ at MOIs of 1 or 10 in
triplicate and incubated for 48h. Cells were then stained for b-gal
expression. Infectability was expressed as a percentage by dividing the
number of b-gal-expressing cells by the total number of cells from three
separate microscopic fields at a magnification of  200. Each value
represents mean7s.d. of three determinations. Data were consistent in
two separate experiments.
Figure 6 Adenovirus-mediated expression of K1–5 in Ad/K1–5-
transduced TCC-SUP cells and tumour xenografts, and its effect on
intratumoral vascularisation. Expressions of K1–5 in TCC-SUP cells (A)
infected with Ad/K1–5 at an MOI of 2 or (B) mock-infected were
determined by immunostained with rabbit antibody against human K1–3
( 200 magnification). Expressions of K1–5 in TCC-SUP bladder tumour
xenografts after treatment with (C) Ad/K1–5 or (D) PBS ( 200
magnification). Reduction of intratumoral vascularisation (E, G) in Ad/K1–
5-treated tumours, but not in (F, H) PBS-treated tumours determined by
immunostained with factor VIII ( 100 magnification). The arrows indicate
the location of microvessels. The insets in G and H represent the magnified
area ( 400 magnification).
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scells regardless of their similar level of infectability by adenovirus.
Furthermore, TSGH-8301 cells were resistant to Ad5WS1-mediated
cell death despite their high infectablity by adenovirus. Ad5WS1
replicated most efficiently in J82 cells, which, however, were least
infectable with adenovirus among the cell lines examined. A recent
study has also shown that CAR expression on TCC-SUP cells is
about four times higher than on J82 cells (van der Poel et al, 2002).
Therefore, our results clearly show that the susceptibility of human
bladder cancer cells to Ad5WS1-induced cytolysis was not
attributed to differences in their infectability by adenovirus. To
confirm the correlation between p53 status and susceptibility to
E1B-55 kD-deleted adenovirus, BFTC-905 cell line and its
derivative BFTC-173-12 transfectant, in which p53 function has
been ablated by expression of a dominant-negative p53 allele, were
used in parallel to determine the susceptibility of the bladder
cancer cells to Ad5WS1-induced cytolysis. Our results demonstrate
that disruption of p53 in bladder cancer cells rendered them more
susceptible to Ad5WS1-induced cytolysis. We also showed that the
higher sensitivity to Ad5WS1 replication in BFTC-173-12 cells
compared with BFTC-905 cells was not attributable to the increase
of infectability, because BFTC-173-12 cells were as infectable by
Ad/LacZ as were the parental BFTC-905 cells. To this end, we have
recently shown that Ad5WS1-induced cytolysis is dependent on
the transcription activity of p53 in hepatocellular carcinoma cells
(Hsieh et al, 2003). Furthermore, introduction of the hepatitis B
virus X gene into liver cells sensitises them to cytolysis induced by
Ad5WS1 through the disruption of p53 transcription activity.
Although antitumour activity of E1B-55 kD-deleted adenovirus
has been demonstrated in a wide range of different human
tumours in vitro and in vivo, the mechanism underlying its
oncolytic activity remains controversial. Recently, E1B-55 kD-
deleted adenovirus has been shown to exert cytotoxic effect in
seven established human bladder cancer cell lines (van der Poel
et al, 2002) in vitro. However, this study did not further investigate
the underlying mechanism. Ries et al (2000) have shown that loss
of p14
ARF, a negative regulator for the MDM2 expression,
facilitates the replication of E1B-55 kD-deleted adenovirus in
tumour cells retaining wild-type p53. This finding supports the
therapeutic use of this mutant adenovirus not only in tumours
with mutant p53 but also in tumours with lesions within the p53
pathway. In bladder cancer, alterations affecting the p53 pathway,
including p53, MDM2, p21
WAF1 and p14
ARF, are frequent events,
which may be important diagnostic and prognostic markers in
patients with bladder cancer (Lianes et al, 1994; Markl and Jones,
1998). As MDM2 ubiquitinates p53 and targets it for proteosomal
degradation, it inactivates the function of p53. In a number of
human cancers, the MDM2 gene is amplified or overexpressed,
leading to inadequate levels of p53. Thus, p53 may be indirectly
inactivated by mechanisms other than p53 mutations in some
bladder cancers. It is plausible that tumour cells in which high
levels of MDM2 suppress p53 may allow E1B-deleted adenovirus
replication. BFTC-905 cells have been shown to overexpress
MDM2 mRNA (Cheng et al, 1995), which may explain in part
why Ad5WS1 at high doses caused CPE, albeit to a very small
extent, in bladder cancer cells harbouring wild-type p53. Further
analysis of the p53 pathway in bladder cancer cells may answer
part of this question. The molecular basis for the growth
differences of E1B-deleted adenovirus within different tumour
and normal cell types remains to be determined.
In a number of clinical trials, E1B-55 kD-deleted adenovirus is
well-tolerated by numerous routes of administration. However, as
a single agent, its therapeutic efficacy for refractory solid tumours
has been limited. Combination therapy seems to have greater
promise in improving its antitumour activity. In the present study,
we employed Ad5WS1 in combination with Ad/K1–5, an
E1-deleted, replication-defective adenoviral vector expressing
angiogenic inhibitors, for the treatment of TCC-SUP bladder
tumour xenografts. Because antiangiogenesis therapy is likely to be
most effective in a low tumour burden state (Bergers et al, 1999),
we started the treatment in mice bearing tumours ranging
approximately from 25 to 48mm
3. Mice with low tumour burdens
have been used in previous reports for evaluation of adenovirus-
mediated antiangiogenic gene therapy (Im et al, 1999; Sauter et al,
Figure 7 Chorioallantoic membrane (CAM) assay of Ad/K1–5. Chorioallantoic membranes of 6-day chick embryos were treated with (A) Ad/K1–5
(2 10
7 PFU), (B) Ad/LacZ (2 10
7 PFU) or (C) PBS. The CAMs were photographed after incubation for 24h at 371C.
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Figure 8 Effects of Ad5WS1 and Ad/K1–5, singly or in combination, on
human TCC-SUP bladder tumour xenograft growth. TCC-SUP cells (10
7)
were inoculated s.c. into the flank of SCID mice at day 0. At day 8 when
visible and palpable nodules developed at all injection sites, groups of seven
mice were treated intratumorally with Ad5WS1 (10
8 PFU) or Ad/K1–5
(2.5 10
8 PFU) alone for 5 consecutive days, or with Ad5WS1 (10
8 PFU)
for 5 consecutive days plus Ad/K1–5 (2.5 10
8 PFU) at days 9 and 11.
Data are presented as mean7s.e.
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s2000). We found that combined therapy of Ad5WS1 and Ad/K1–5
was superior to either treatment alone in inhibiting tumour
growth. E1B-55 kD-deleted adenovirus has been shown to act as a
helper virus and augment the expression of the accompanying
cytokine genes delivered by replication-defective adenoviral vector
(Motoi et al, 2000). Although antiangiogenic therapy targets
genetically stable endothelial cells in the tumour vasculature,
tumour cells with mutated p53 are less susceptible to apoptosis
under hypoxic conditions, resulting in reducing their reliance on
vascular supply, and hence their responsiveness to antiangiogenic
therapy (Yu et al, 2002). As tumour cell populations may be
heterogeneous in terms of genetic mutations in clinical settings,
combination therapy targeting to different types of tumour cells
would be expected to enhance therapeutic efficacy. To this end, the
strategy of combination therapy of oncolytic E1B-deleted adeno-
virus with adenoviral vector encoding angiogenic inhibitors is
more desirable in clinical settings, as cancer cells with nonfunc-
tional p53 would be more susceptible to Ad5WS1-induced
cytolysis than those with wild-type p53, while tumours retaining
functional p53 more responsive to antiangiogenic therapy because
of more vascular dependence. Several phase I/II clinical trials of
oncolytic adenoviruses for head and neck, pancreatic, ovarian and
gastrointestinal carcinomas have been carried out. However,
oncolytic adenoviral therapy has not been applied to the patients
with bladder cancer. Owing to the fact that intact urothelium can
function as an effective barrier, bladder is suitable for intravesical
instillation of oncolytic E1B-deleted adenovirus or adenoviral
vectors. In line with this notion, intravesical instillation of
adenoviral vectors has been shown recently to be safe, feasible
and biologically active in patients with bladder cancer (Kuball et al,
2002).
In conclusion, our results demonstrate that E1B-55 kD-deleted
adenovirus caused more severe cytolytic effect and replicated more
efficiently in bladder cancer cells with mutant p53 than in those
with wild-type p53. In the bladder xenograft animal model, it also
exerted antitumour effects, which could be augmented by
combining with replication-defective adenoviral vector expressing
K1–5. Therefore, our results suggest that E1B-55 kD-deleted
adenovirus may have therapeutic potential, especially in combina-
tion with adenoviral vector expressing K1–5, for the treatment of
patients with bladder cancer.
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